Sotelo, M.
Alonso-Gordoa, T.
Gajate, P.
Gallardo, E.
Morales-Barrera, R.
Pérez-Gracia, J. L.
Puente, J.
Sánchez, P.
Castellano, D.
Durán, I. http://orcid.org/0000-0001-8571-7163
Funding for this research was provided by:
Roche Farma, Spain
Article History
Received: 5 June 2020
Accepted: 18 August 2020
First Online: 8 September 2020
Compliance with ethical standards
:
: Teresa Alonso Gordoa has received honoraria for consultancy/advisory or speaker from Ipsen, Pfizer, Roche/Genentech, Sanofi, Bayer, Astellas, Janssen-Cilag, Merck Sharp & Dohme, Bristol-Myers Squibb and Eisai. Pablo Gajate has received honoraria for participation in advisory boards from Roche; as a speaker from Pfizer, Bristol-Myers Squibb and Roche/Genentech; and travel expenses from Pfizer and Roche/Genentech. Enrique Gallardo has received honoraria for Consultant or Advisory Role: Sanofi, Janssen, Astellas, Pfizer, Bayer, Roche, Ipsen, Novartis, Eisai, EUSA Pharma, BMS, AstraZeneca, Merck, Rovi, Daiichi Sankyo, Techdow. Speaking Role: Astellas, Janssen, Sanofi, Bayer, Ipsen, Pfizer, Roche, BMS,Novartis, Rovi, Daiichi Sankyo, Leo Pharma, Menarini, Eisai, MSD, Boehringer, Ingelheim, Merck. Grant support (personal/institutional): Astellas, Janssen, Sanofi, Pfizer, Bayer,Ipsen, Roche, Ferrer, GSK, BMS. Travel expenses: Astellas, Janssen, Sanofi, Bayer, Ipsen, Roche, Novartis, Pierre Fabre, Pfizer, Eisai. Rafael Morales Barrera has received honoraria for consulting, advisory and/or speaker bureaus from Sanofi, Bayer, Janssen, AstraZeneca, Merck Sharp & Dohme, Asofarma; and received travel and accommodations expenses from Roche/Genentech, Sanofi, Astellas, Janssen, Merck Sharp & Dohme, Bayer, Pharmacyclics, Clovis and Eli Lilly. Jose Luis Pérez Gracia has received research grants and support from Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, Ipsen, Eisai, Incyte and Janssen; honoraria as a speaker and as part of advisory boards from Roche/Genentech, Bristol-Myers Squibb, Ipsen, Eisai, Merck Sharp & Dohme and Seattle Genetics; and travel support from Roche/Genentech, Merck Sharp & Dohme and Bristol-Myers Squibb. Javier Puente has received honoraria as consultant/advisor or speaker from Pfizer, Astellas, Janssen, MSD, Bayer, Roche/Genentech, Bristol-Myers Squibb, Boehringer, AstraZeneca, Ipsen, Novartis, Eusa Pharma, Eisai, Pierre-Fabre, Merck and Sanofi; and research funding from Astellas, Pfizer and Roche/Genentech. Ignacio Durán has received honoraria from Bristol-Myers Squibb, Ipsen, Roche/Genentech, Janssen, MSD, Astellas and Eusa Pharma; consulting/advisory boards from Roche/Genentech, Merck Sharp & Dohme, Bayer, Bristol-Myers Squibb, Seattle Genetics, Pharmacyclics, Janssen and Novartis; research funding from Roche/Genentech, AstraZeneca.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional reserach committee and with the 1964 Helsinki declarartion and its later ammendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: Patients already gave their consent to participate in the corresponding trials.
: All authors have consented to submission of this article for publication.
: “Qualified researchers may request access to individual patient level data through the clinical study data request platform (ExternalRef removed). Further details on Roche’s criteria for eligible studies are available here. (ExternalRef removed). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here. (ExternalRef removed<u>)</u>.”